BioLineRx Ltd. (NASDAQ: BLRX)
a biopharmaceutical drug development company, announced today that it
has signed an exclusive, worldwide license agreement with Biokine
Therapeutics Ltd., a Clal Biotechnology Industries (TASE: CBI) portfolio
company, for the development and commercialization of BL-8040 (formerly
BKT-140), a Phase II ready drug candidate for the treatment of acute
myeloid leukemia (AML), as well as other types of hematological cancer.
BL-8040 is a short peptide that functions as a high-affinity antagonist
for CXCR4, a chemokine receptor that is directly involved in tumor
progression, angiogenesis (growth of new blood vessels in the tumor),
metastasis (spread of the disease to other organs or organ parts) and
cell survival. CXCR4 is over-expressed in more than 70% of human cancers
and its expression often correlates with disease severity. In a Phase
I/II, open-label, dose escalation, safety and efficacy clinical trial in
16 multiple myeloma patients, BL-8040 demonstrated an excellent safety
profile and was well tolerated at all doses tested. On the basis of data
obtained from this study, the FDA has approved an IND application.
BL-8040 has been shown to induce the mobilization of healthy
hematopoietic stem cells from the bone marrow into the peripheral blood.
BL-8040 also mobilizes cancer cells from the bone marrow and other sites
and may therefore expose these cells to chemo- and bio-based anti-cancer
therapy and induce apoptosis (cell death). Pre-clinical studies show
that BL-8040 is efficient, both alone and in combination with the
anti-cancer drug Rituximab, in reducing bone marrow metastasis of
lymphoma cells and stimulating lymphoma cell death.
Dr. Kinneret Savitsky, CEO of BioLineRx, commented, "BioLineRx has made
a strategic decision to enter the field of oncology, where there is
clearly an urgent need for next generation anti-cancer therapies
utilizing novel biological pathways. We are therefore extremely pleased
to in-license this promising Phase II ready drug, which we will
initially develop for the treatment of acute myeloid leukemia, a true
unmet medical need with very low survival rates. AML is a recognized
orphan indication both in the U.S. and the EU; therefore, we plan to
seek orphan designation status from the regulatory authorities in order
to accelerate its development plan. In addition, based on BL-8040's
promising pre-clinical data, as well its mechanism of action, we believe
it can be utilized for several other related oncology indications and we
intend to explore these possibilities as well. We look forward to the
upcoming Phase II clinical study for evaluating BL-8040's efficacy on
AML patients, which is expected to commence in the first half of 2013."